Drug
F2695
F2695: highest development phase Phase 3, developed by Pierre Fabre. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Pierre Fabre
Trials
| Drug | Phase | Indication |
|---|---|---|
| F2695 NCT01639014 | Phase 3 | Ischemic Stroke |
| F2695 NCT02266966 | Phase 1 | Subject |
Latest
No recent events.
Follow F2695 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.